Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 162   

Articles published

NVS 86.53 +0.13 (0.15%)
price chart
How Analysts Rated Novartis AG (ADR) (NYSE:NVS) Last Week?
Out of 3 analysts covering Novartis Ag (NYSE:NVS), 2 rate it “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive.
Trade of the Day: It's Not Too Late to Short NVS Stock
Novartis AG (ADR) Entresto Clinches EU approval
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Heart Failure Drug Entresto Approved By European Commission ...  The
Notable Runners: Biogen Inc (NASDAQ:BIIB), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) lost -0.30% and closed the last trading session at $86.39. The market capitalization of the company is $238.26 billion with the total traded volume of the company is 1.62 million.
Trending European stocks: XL Group plc (NYSE:XL), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) was at $86.40 in the last trading session after the stock fell -0.29%. The market capitalization of the company is $238.29 billion with the total outstanding shares of 2.40 billion.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Cambridge Trust Company Increased Novartis Ag Sponsored Adr (NYSE:NVS) by $11 ...
Cambridge Trust Company increased its stake in Novartis Ag Sponsored Adr (NYSE:NVS) by 983.26% based on its latest Q3 2015 regulatory filing with the SEC.
Technical Report on Novartis AG (ADR) (NYSE:NVS)
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ...
Novartis AG (ADR) (NVS) Earnings Per Share Expected to Increase
Analysts await Novartis AG (ADR) (NYSE:NVS) to reports earnings on October, 27. They expect $1.32 EPS, up 3.13% or $0.04 from last year's $1.28 per share.
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Here's Why Novartis AG (ADR) Fared Better Than Others
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA  CNA Finance (press release)